The brand pharmaceutical lobby says recent statements by some drug companies to their shareholders that the new maximum fair prices negotiated by Medicare for their products will not throw them off financially should not be taken as a sign that the Inflation Reduction Act’s drug price negotiation program won’t hinder the potential for innovation of crucial medicines in the future, in an email shared with reporters Tuesday (Aug. 20). When asked to clarify, the lobby group told Inside Health Policy...